Intra-tumoral delivery of functional ID4 protein via PCL/maltodextrin nano-particle inhibits prostate cancer growth
Open Access
- 30 July 2016
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (42) , 68072-68085
Abstract
Oncotarget | https://doi.org/10.18632/oncotarget.10953 Maxwell Korang-Yeboah, Divya Patel, Derrick Morton, Pankaj Sharma, Yamini Gorantla, Jugal Joshi, Perri Nagappan, Ravi Pallaniappan, Jaideep Chaudhary Intra-tumoral delivery of functional ID4 protein via PCL/Maltodextrin nano-particle inhibits prostate cancer growthKeywords
This publication has 45 references indexed in Scilit:
- Id4 dependent acetylation restores mutant-p53 transcriptional activityMolecular Cancer, 2013
- Id4 deficiency attenuates prostate development and promotes PIN-like lesions by regulating androgen receptor activity and expression of NKX3.1 and PTENMolecular Cancer, 2013
- Id1 and Id3 expression is associated with increasing grade of prostate cancer: Id3 preferentially regulates CDKN1BCancer Medicine, 2012
- Epigenetic inactivation of inhibitor of differentiation 4 (Id4) correlates with prostate cancerCancer Medicine, 2012
- Clinical impact of serum proteins on drug deliveryJournal of Controlled Release, 2012
- Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate CancerCancer Research, 2010
- Targeted Delivery of Protein Drugs by NanocarriersMaterials, 2010
- Docetaxel down‐regulates the expression of androgen receptor and prostate‐specific antigen but not prostate‐specific membrane antigen in prostate cancer cell lines: Implications for PSA surrogacyThe Prostate, 2009
- Inhibitor of differentiation 4 (Id4) is a potential tumor suppressor in prostate cancerBMC Cancer, 2009
- DocetaxelDrugs, 1996